CCND1 and breast cancer: In vitro drug sensitivity studies suggest deregulated Cyclin D1 may contribute to HNSCC chemoresistance, and CDK4/6 inhibitors that inhibit Cyclin D1 activity have shown substantial clinical improvement in breast cancer [56,57,58].